Eisai also announced initiation of a Phase II study (Study 202) on E2814 for sporadic early Alzheimer's Disease (AD).
Impact of the anti-MTBR tau antibody E2814 on tau pathology biomarkers in Dominantly Inherited Alzheimer's Disease (DIAD)E2814 is an investigational anti-MTBR tau antibody designed to target the MTBR of tau.
Initiation of Phase II clinical study (Study 202)In September 2024, Eisai initiated a Phase II clinical study (Study 202) for individuals with early AD in the United States.
Biomarkers related to AD tau pathologyAs fluid biomarkers related to AD tau pathology, tau containing the residue 243 (MTBR-tau243) and tau phosphorylated at theresidue 217 (p-tau217) in CSF have been reported.1 In addition, positron emission tomography (tau PET), which specifically detects tau aggregates, is used as an imaging biomarker.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.

Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) By Investing.com